Literature DB >> 23736908

Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome.

Matteo Molica1, Adriano Salaroli1, Giuliana Alimena1, Massimo Breccia1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23736908      PMCID： PMC3934268          DOI： 10.2450/2013.0005-13

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  5 in total

1.  Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response.

Authors:  Massimo Breccia; Giuseppina Loglisci; Adriano Salaroli; Laura Cannella; Michelina Santopietro; Giuliana Alimena
Journal:  Acta Haematol       Date:  2010-07-09       Impact factor: 2.195

Review 2.  Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review.

Authors:  Roberto Guariglia; Maria Carmen Martorelli; Oreste Villani; Giuseppe Pietrantuono; Giovanna Mansueto; Fiorella D'Auria; Vitina Grieco; Gabriella Bianchino; Rosa Lerose; Giovanni Battista Bochicchio; Pellegrino Musto
Journal:  Leuk Res       Date:  2010-12-23       Impact factor: 3.156

Review 3.  An update on iron chelation therapy.

Authors:  Erika Poggiali; Elena Cassinerio; Laura Zanaboni; Maria Domenica Cappellini
Journal:  Blood Transfus       Date:  2012-06-27       Impact factor: 3.443

4.  Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.

Authors:  Norbert Gattermann; Carlo Finelli; Matteo Della Porta; Pierre Fenaux; Michael Stadler; Agnes Guerci-Bresler; Mathias Schmid; Kerry Taylor; Dominique Vassilieff; Dany Habr; Andrea Marcellari; Bernard Roubert; Christian Rose
Journal:  Haematologica       Date:  2012-03-14       Impact factor: 9.941

5.  Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.

Authors:  Massimo Breccia; Paola Finsinger; Giuseppina Loglisci; Vincenzo Federico; Michelina Santopietro; Gioia Colafigli; Luigi Petrucci; Adriano Salaroli; Alessandra Serrao; Roberto Latagliata; Giuliana Alimena
Journal:  Ann Hematol       Date:  2012-05-09       Impact factor: 3.673
  5 in total
  3 in total

1.  Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy.

Authors:  Pasquale Niscola; Andrea Tendas; Laura Scaramucci; Roberta Merola; Gianfranco Catalano; Paolo de Fabritiis
Journal:  Blood Res       Date:  2014-06-25

2.  Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis.

Authors:  Elena Maria Elli; Angelo Belotti; Andrea Aroldi; Matteo Parma; Pietro Pioltelli; Enrico Maria Pogliani
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-06-01       Impact factor: 2.576

3.  Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes.

Authors:  Mathieu Meunier; Sarah Ancelet; Christine Lefebvre; Josiane Arnaud; Catherine Garrel; Mylène Pezet; Yan Wang; Patrice Faure; Gautier Szymanski; Nicolas Duployez; Claude Preudhomme; Denis Biard; Benoit Polack; Jean-Yves Cahn; Jean Marc Moulis; Sophie Park
Journal:  Oncotarget       Date:  2017-11-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.